ÂÜÀòÂÒÂ×

Jeffrey K. Allen is the founder, president, and CEO of TumorGen. Jeffrey has over 25 years of experience in the field of diagnostics and has held various positions in marketing and product management.

Jeffrey started their career in 1991 as a market planning manager at Beckman Coulter. Jeffrey then moved to Gen-Probe Incorporated in 1998 where they became a senior product manager for instrumentation. In 2008, they joined BD Diagnostics as an associate director of strategic marketing.

At BD Diagnostics, Jeffrey was responsible for impacting the strategic direction of next generation blood stream infection (BSI) detection. Jeffrey also conducted market analyses for new molecular-based diagnostic assays targeting infectious diseases. In 2009, they researched and delivered a market analysis and positioning strategy for a new H1N1 molecular assay.

In 2010, Jeffrey left BD Diagnostics to start TumorGen, a company that specializes in developing diagnostic tests for cancer. Under their leadership, TumorGen has become a leading player in the field of cancer diagnostics, with its tests being used by hospitals and clinics around the world.

Jeffrey K. Allen completed their undergraduate studies in biochemistry at the University of Massachusetts Amherst. Jeffrey then went on to complete their Ph.D. in analytical chemistry at Arizona State University.

A direct report to Jeffrey K. Allen is and Peter Teriete - Scientific Co-Founder.